Insight

Glioblastoma awareness day

Published

2 years ago

July 22, 2021

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) is an oncology-focused drug development company.

Their lead program is paxalisib, which is being developed to treat glioblastoma (GBM), the most common and aggressive form of primary brain cancer in adults. There are few treatment options for sufferers of GBM and around 65% of sufferers do not respond to currently available treatments. The condition affects around 133,000 people globally per annum and the potential addressable market is worth more than US$1 billion.

Kazia’s drug paxalisib, commenced recruitment to GBM AGILE, a pivotal study in glioblastoma, in January 2021. Eight additional studies are active in various forms of brain cancer. Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the US FDA in August 2020. Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data for EVT801 has shown it to be active against a broad range of tumour types and has provided compelling evidence of synergy with immuno- oncology agents.

A phase I study is expected to begin in CY2021. Competitive Advantages: – Lead program, paxalisib, sourced from the world’s most successful cancer drug developer, Genentech – Experienced team with extensive backgrounds in big pharma and biotech – Around 65% of GBM sufferers do not respond to current treatments – Multiple shots on goal with collaborations progressing in other cancers; largely funded by participating hospitals.

For more information, head to their website.

Insight

Revolutionising property ownership with property syndication

Published

5 days ago

September 28, 2023

Ticker News Insight - Sponsored Content

What are the benefits of property syndication?

In a world where property prices seem to be continually soaring, George Rodman’s innovative approach of property syndication offers everyday Australians a chance to overcome the mounting challenges of property ownership.

Discover how this bold idea works, its numerous benefits, and how it holds potential even for those concerned about the associated risks, all while hearing George’s personal motivation that stems from his own upbringing.

Insight

The BPA found in popular activewear

Published

1 week ago

September 25, 2023

Ticker News Insight - Sponsored Content

BPA and heavy metals have been found in some popular branded active wear

In a recent studies across the U.S, a variety of popular branded sports bras and athletic wear have been found to contain alarming levels of BPA, a chemical compound frequently used in the production of certain types of plastics.

The discovery of BPA in these textiles has raised concerns regarding its potential adverse health effects, which include asthma, cardiovascular disease, and obesity.

Clayton Thomas, CEO of The Root Brands, offers his perspective on this unexpected revelation, where BPAs presence in fabrics used for sports and active wear has puzzled many, given that BPA has long been a target of avoidance and regulatory scrutiny due to its health risks.

The Green Edition is presented by The ROOT Brands.

For all media inquiries, please get in touch here: tshuvah4u@yahoo.com.

Insight

Global market forces and OCIO adoption

Published

2 weeks ago

September 21, 2023

Ticker News Insight - Sponsored Content

Do global markets and economic climate influence OCIO adaption with investors?

In a recent Institutional Investor report, the outsourced chief investment officer (OCIO) industry is on the brink of substantial growth, driven by increasing interest from asset owners, especially endowments and foundations, who are increasingly turning to OCIO services.

To delve deeper into this trend, we are privileged to introduce Jim Schienberg, Managing Partner at North Pier Search Consulting, a renowned OCIO search firm.